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Abstract: Malnutrition represents a major problem in the clinical management of the inflammatory
bowel disease (IBD). Presently, our understanding of the cross-link between eating behavior and
intestinal inflammation is still in its infancy. Crohn’s disease patients with active disease exhibit strong
hedonic desires for food and emotional eating patterns possibly to ameliorate feelings of low mood,
anxiety, and depression. Impulsivity traits seen in IBD patients may predispose them to palatable
food intake as an immediate reward rather than concerns for future health. The upregulation of
enteroendocrine cells (EEC) peptide response to food intake has been described in ileal inflammation,
which may lead to alterations in gut–brain signaling with implications for appetite and eating
behavior. In summary, a complex interplay of gut peptides, psychological, cognitive factors, disease-
related symptoms, and inflammatory burden may ultimately govern eating behavior in intestinal
inflammation.
Keywords: enteroendocrine cells; enteroendocrine peptides; gut hormones; gut–brain axis; intestinal
inflammation; eating behavior
1. Introduction
Malnutrition represents a major problem in the clinical management of the inflamma-
tory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis (UC). Malnutrition
may be attributed to poor nutritional intake, micronutrient deficiencies due to impaired
utilization or loss of nutrients, malabsorption due to mucosal inflammation or resection [1].
Further, the negative nitrogen balance observed in CD is related to increased protein
catabolism rates [2] in response to increased protein requirements attributed to intestinal
and systemic inflammation (e.g., acute-phase protein, pro-inflammatory cytokine, and fecal
calprotectin FCP production). Several other factors such as disease burden, appetite loss,
disordered eating, and other associated symptoms such as nausea, diarrhea contribute to
malnutrition with a negative impact on IBD patients’ quality of life. In this review, we will
present the current understanding of the effect of intestinal inflammation on gut–brain
signaling and eating behavior.
2. Methods
A literature search was performed on PubMed (National Library of Medicine) using
search terms: intestinal inflammation, inflammatory bowel disease, Crohn’s disease, Ulcer-
ative colitis, enteroendocrine cells, enteroendocrine cell peptides, gut hormones, brain MRI,
gut–brain axis, and eating behavior. All research articles were considered based on the
priority scale as follows: systematic reviews, and meta-analyses, randomized controlled
trials (RCTs), human observational studies, case studies, animal and in vitro studies. We
selected publications between January 1978 and December 2020. Of the selected articles,
the full texts and the references were reviewed, and if the reference list contained eligible
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articles those were also included. All publication not written in the English language were
excluded.
3. Eating Behavior in IBD
Malabsorption and catabolism are considered to be the major contributors to weight
loss in IBD. However, suppressed appetite, early satiety, and reduced food intake are also
clinically relevant in the etiology of nutritional abnormalities in IBD patients [3]. Appetite
can be described as “the internal driving force for the search, choice, and ingestion of
food” [4]. The intake of food results in satiation that decreases the drive to eat thereby
terminating an eating episode, which leads to a feeling of satiety that inhibits hunger and
determines the quantity of food consumed at the next eating episode [5]. Food intake
is governed by complex neurohormonal appetite networks involving homeostatic and
hedonic factors. Disordered eating might be linked with a disruption in homeostatic and
hedonic balance. Presently, our understanding of the cross-link between eating behavior
and IBD is still in its infancy. Patients with gastrointestinal disorders are at a higher risk of
disordered eating patterns such as meal skipping, food restriction, and binge eating [6,7].
A survey investigating dietary beliefs and behaviors in IBD patients showed that 48%
believed diet was the initiating factor in IBD and 57% believed it could trigger a flare [8].
Certain foods such as (sugary food, coffee/tea, carbonated beverages, milk/milk products,
raw vegetables/fruits, alcohol, fatty food, and spicy food) were implicated in worsening
symptoms, hence avoided to reduce symptoms [8–10].
A disordered eating behavior may be described with a two-path theoretical model [6,7].
The first pathway describes feelings of heightened anxiety about unfamiliar foods and
overestimation of the negative consequences linked with their disease. The second pathway
describes the type of behavior that employs techniques to lose weight to counteract weight
gain induced by medical or dietary interventions. Disordered eating in CD patients
during active disease has been previously reported [11]. CD patients reported greater
anxiety/depression, greater emotional eating, lower positive mood, greater binge eating
tendencies, lower craving control, and greater craving for sweet and savory foods. Reduced
protein consumption was found in males and carbohydrates in females [11]. However,
other studies have shown no difference in energy intake but suboptimal micronutrient
intakes in both active and inactive CD [12,13]. Anxiety about food intake in CD patients
may lead to restriction of food groups to minimize fear of worsening symptoms [7]. Anxiety
and depression in IBD are complex issues that could be a manifestation of several factors,
e.g., lower socioeconomic status [14], poor quality of life due to chronic fatigue [15],
pain [16], and extraintestinal manifestations [17]. CD patients may exhibit increased food
monitoring behaviors, often seen in people with gastrointestinal disorders [6,7,11]. The
role of energy-dense food in alleviating low mood also called “comfort eating” has been
demonstrated in healthy individuals, where neural responses in key hedonic brain regions,
including midbrain, dorsal and ventral striatum, left anterior cingulate cortex (ACC) right
hippocampus, and homeostatic regions such as the hypothalamus and brainstem were
attenuated by a fatty acid infusion in an experimentally induced sad mental state [18].
CD patients may have stronger hedonic desires for food and emotional eating patterns
possibly to alleviate symptoms of low mood, anxiety, and depression [11]. A recent study
found an association between the inflammatory potential of diet, as assessed by Dietary
Inflammatory Index (DII) [19] and disease severity in CD but not in UC [20]. Palatable
but, pro-inflammatory foods found in the Western diet may provide immediate reward but
worsen CD severity in the long term. Longitudinal studies are needed to investigate the
effect of diet on disease course.
Personality traits such as impulsivity may also influence eating behaviors in IBD
patients. Impulsivity has been described as 3 distinct psychological manifestations, i.e.,
impulsive choice, impulsive action, and reflection impulsivity [21]. An impulsive choice
represents a measure of reward sensitivity whereby a person tends to accept small or
immediate rewards instead of larger future outcomes [22]. Impulsive action represents the
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inability to inhibit an inappropriate reaction to prepotent stimuli [22]. Reflection impulsiv-
ity describes the failure to gather essential information and evaluate this information before
making a decision [23]. A study that examined different personality traits in IBD [24], found
that impulsive choice as assessed by the Eysenck Impulsivity Inventor [25], was higher in
IBD patients (both with UC and CD) compared with controls. Further, elevated impulsivity
was associated with low levels of physical and mental health and poorer quality of life in
IBD patients, which was more characteristic of the female gender [24]. Another study [26],
which investigated “impulsive sensation seeking” (ImpSS) personality characteristic in
IBD found that smokers with CD had higher ImpSS scores than smokers with UC. Smokers
with CD also scored higher on the nicotine dependence scale than smokers with UC [26].
Impulsivity is a personality trait that predisposes toward rewarding behavior, which may
explain smoking behaviors in CD due to the rewarding properties of nicotine that is linked
with the mesolimbic dopaminergic system [27]. The mesolimbic dopaminergic system
also dictates the reward and pleasure-driven liking and wanting of food [28]. If inhibitory
control is impaired, the preference for palatable foods becomes more appealing as an
immediate reward than future health concerns. Taken together, a complex phenomenon
involving reward and impulse-driven food choices to ameliorate symptoms such as low
mood, abdominal pain, and chronic fatigue may influence eating behaviors in IBD.
4. Physiology of Appetite Regulation
The enteroendocrine gut–brain axis plays a critical role in the homeostatic regulation
of appetite. The enteroendocrine system is the largest endocrine organ in the human body
and it is made up of enteroendocrine cells (EEC) [29]. EEC are found distributed as single
cells throughout the intestinal tract and are located within intestinal crypts and villi and
represent 1% of cells lining the intestinal epithelium [29]. Gastrin, ghrelin, somatostatin,
cholecystokinin (CCK), glucose-dependent insulinotropic peptide (GIP), glucagon-like
peptide (GLP-1), and peptide YY (PYY) are some of the peptides secreted by EEC [30].
Ghrelin is secreted by the stomach and enhances appetite [31], whereas CCK, PYY, and
GLP-1 suppress appetite [32]. EEC act as sensors of the luminal nutrient content either in a
classical endocrine fashion or by paracrine effect on proximal cells, notably vagal afferent
fibers [33], and secrete peptides and amines that regulate postprandial gut secretion and
motility [34]. Food-induced stretching of the stomach muscle wall signals through the
gastric mechanoreceptors and activates the vagus nerve. The vagus nerve is made up
of both afferent fibers (visceral sensory nerve) and efferent fibers (motor nerves) [35].
Peripheral vagal afferent fibers are scattered along with the mucosal and submucosal layers
of the digestive tract. The EEC peptides act on vagal afferents in the gastrointestinal tract
directly relaying signals to the CNS through the nucleus tractus solitarius (NTS) [36], to
regulate ingestive behavior [37]. Some of the key EEC peptides (CCK, PYY, GLP-1, and
ghrelin) are described below.
4.1. CCK
CCK is one of the first endogenous gut hormones documented to affect appetite and a
neuropeptide that is abundantly found in the CNS [38]. CCK is synthesized and released
from the I cells of the proximal duodenum and jejunum in response to luminal content,
particularly, protein and fat [39]. It has a short half-life of 1–2 min (i.e., rapidly deactivated
after release). Long-chain fatty acids of chain length C12 can stimulate I cells to release
CCK [40] via G-protein-coupled receptor 40 [41]. CCK exerts its effects via receptors CCK-1
and CCK-2. CCK-1 is found in the gastrointestinal tract and CCK-2 is expressed in the
CNS [5]. CCK binds to its CCK-1 receptor on the sensory terminals of the vagus nerve
relaying satiety signals to the arcuate nucleus (ARC) in the hypothalamus [42]. Peripheral
administration of CCK reduces appetite and meal size in rodents and humans [43]. CCK-1
receptor knockout rats exhibit an increase in food intake and develop an obese phenotype,
attributed to the overexpression of neuropeptide Y (NPY) [44]. A high dose of intravenous
administration of CCK can induce nausea and abdominal discomfort, contributing to the
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reduction in food intake [45]. CCK levels rise over 10–30 min after food ingestion and act
to stimulate gall bladder contraction, pancreatic secretions, and delayed gastric emptying,
collectively contributing to the feeling of fullness and satiety [39]. Central administration
of CCK agonists via intracerebroventricular injections reduces food intake in rodents [46].
Finally, the central administration of CCK with leptin induces weight loss in rodents
indicating the role of CCK in enhancing the effect of leptin in the regulation of appetite [47].
4.2. GLP-1
GLP-1 is released from the L cells in the distal small intestine and proximal colon
proportionately to ingested carbohydrate load [48]. GLP-1 is released rapidly into the
circulation with a biphasic response to food intake mainly carbohydrates (CHO). It is
released 10–15 min postprandially and again peaks after 30–60 min [5]. The initial re-
lease of GLP-1 is vagally mediated [49] or due to stimulation of GLP-1/GIP co-expressing
K cells. The later release of GLP-1 is due to direct stimulation of ileal L cells [50]. Pe-
ripheral and central administration of GLP-1 and GLP-1 receptor agonists (exendin-4)
show reduced food intake in rodents [51]. The GLP-1 receptors in the CNS rather than
the vagus nerve contribute to the complete anorectic response to the GLP-1 agonist li-
raglutide, suggesting that GLP-1 receptors in the CNS are involved in weight loss [52].
GLP-1 signals converge on the NTS and in the area postrema (AP) and directly activate
pro-opiomelanocortin/cocaine- and amphetamine-regulated transcript (POMC/CART)
and indirectly inhibit the NPY/agouti-related peptide (NPY/AgRP) via GABAergic trans-
mission to reduce food intake [53]. Further, fluorescently labeled liraglutide penetrates the
brain activating GLP-1 receptor-expressing neurons in the ARC to induce weight loss in
rodents [54]. Liraglutide alters brain activity in response to highly palatable food cues in
Type 2 diabetic patients (T2DM) [55]. This finding is in agreement with another study that
showed that liraglutide improved hypo-responsiveness to palatable food in obese T2DM
patients relative to lean healthy controls, indicating the role of GLP-1 in the hedonic control
of food intake [56]. GLP-1 is also an incretin hormone that stimulates insulin biosynthesis
by acting on pancreatic   cell receptors in response to glucose load and regulates glucose
homeostasis [43]. GLP-1 exerts its satiating effects via ileal brake, a feedback mechanism
where distal intestinal signals inhibit proximal gastrointestinal motility and gastric empty-
ing [39]. Finally, the presence of GLP-1 receptors in the (AP) has been linked to side effects,
i.e., nausea and vomiting, of GLP-1 analogues [57].
4.3. PYY
PYY is synthesized and released from the L cells in the ileum and colon in response
to food intake, especially fat and fermentable CHO [38]. PYY concentrations are low in
a fasting state and rise postprandially, in proportion to the energy intake signaling the
appetite-regulating circuits to subsequently reduce food intake [58]. As with GLP-1, PYY
also shows a biphasic response with levels rising within 30 min after meal intake [59]. The
early increase in PYY is CCK mediated [60] while the later increase is due to direct nutrient
stimulation of L cells in the ileum [61]. PYY binds to G protein receptors Y1 and Y2 [5]
and exerts its anorectic effects by acting on the Y2 receptor (Y2R), as evidenced by the
inhibition of food intake in response to Y2R agonist [62] with this effect being dampened
by Y2R antagonist [63]. Y2R is expressed on both NPY and (AGRP) orexigenic neurons in
the hypothalamus and induces its anorectic effects by inhibiting NPY/ARGP neurons via
Y2R and activating the anorexigenic POMC neurons [64]. Further, Y2R is also expressed
by the vagal afferent terminals; the peripheral administration of PYY induces anorectic
effects via the arcuate neuronal activation, and vagotomy or transection of hindbrain-
hypothalamic pathways abolishes this effect [65]. In addition to PYY’s direct central effect
on appetite, PYY also modulates gut motility via ileal brake, through delay in gastric
emptying and gastrointestinal transit time [66], resulting in a sensation of fullness and
satiety [58]. Supraphysiological intravenous infusions of PYY have shown to induce nausea
in humans, thereby having a negative impact on food intake [67].
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4.4. Ghrelin
Ghrelin is an orexigenic hormone secreted by X/A cells in the mucosa throughout
the length of the GI tract, with the highest abundance in the gastric fundus in the stomach.
Circulating ghrelin is significantly increased during fasting and attenuated following a
meal. Central and peripheral administration of ghrelin stimulates food intake leading to
an increase in bodyweight [68]. These effects are diminished after vagotomy, indicating a
gut–brain signaling pathway [31]. The appetite stimulatory action of ghrelin is mediated
through direct stimulation of the orexigenic AgRP/NPY neurons and concomitant inhibi-
tion of the anorectic POMC/CART neurons in the ARC [69]. In addition to its orexigenic
effects, ghrelin also acts as an anabolic hormone that drives lipogenesis [70]. Ghrelin is also
a key regulator of glucose homeostasis, by protecting against hypoglycemia via growth
hormone (GH) release from the anterior pituitary [71], increasing glucagon secretion [72],
and blocking insulin secretion [73]. Ghrelin is a critical hormone implicated in stress re-
sponse. Ghrelin may target the ventral tegmental area (VTA), hippocampus, and amygdala
to modulate reward processes by enhancing feeding during a stress response, as a coping
mechanism to protect against damage associated with chronic stress [74]. Ghrelin also acts
as an anti-inflammatory hormone, inhibiting acute phase protein and pro-inflammatory
cytokine expression [75]. The upregulation of ghrelin observed in acute and chronic inflam-
matory conditions has been attributed to a host’s attempt to restore homeostatic balance
via regulating food intake, body weight, and inflammation [76].
5. Gut–Brain Axis
Appetite regulation involves complex interactions of homeostatic and hedonic factors.
Hypothalamus is central in the homeostatic control of food intake and other neural circuits
integrate environmental and emotional cues to constitute the hedonic drive of appetite
regulation. The ARC of the hypothalamus plays a pivotal role in the integration of signals
regulating appetite. Due to the presence of a relatively leaky blood–brain barrier (BBB) and
the ARC proximity to the median eminence (ME), circulating peripheral hormonal signals
have relatively greater access to receptors in the ARC than other brain areas [38]. ARC
comprises neurons that integrate signals of nutritional status and energy expenditure. Neu-
rons that express POMC and CART are anorexigenic, whereas neurons that express (AgRP)
and (NPY) are orexigenic [77]. Peripheral hormonal signals act on the hypothalamus to
inhibit or activate ARC neurons to alter appetite. Further, ARC neurons also communicate
with other orexigenic and anorexigenic neurons in other nuclei of the hypothalamus to
regulate food intake [78]. Reward pathways activated in response to food comprise the
dopaminergic neurons that originate in the VTA and substantia nigra (SN) in the midbrain
with neuronal projections throughout the brain. Dopaminergic signals are received and
integrated into the nucleus accumbens, striatum, and orbitofrontal cortex (OFC). These
regions are activated in response to food cues and food intake during functional magnetic
resonance imaging (fMRI) scans in humans [79]. Homeostatic and hedonic systems are
integrated via the lateral hypothalamic area (LHA) [80] and through its projections regulate
the VTA and brainstem nuclei such as the NTS, which is pivotal in the modulation of
gut hormones and satiety signals [81]. CCK, GLP-1, and PYY also stimulate the reward
circuitry either directly or through projections from the hypothalamus and brainstem
nuclei such as the NTS [82]. A systematic review of (fMRI) studies has shown associations
between ghrelin, leptin, CCK, GLP-1, and PYY with activations in the hypothalamus, OFC,
ACC, insula, and amygdala. These findings reflect gut–brain interactions during food
intake within the homeostatic regulatory framework [83]. Following food ingestion, the
circulating adipose signals (ghrelin and insulin) cross the BBB and stimulate receptors
on neurons in the hypothalamus. Satiety signals generated by ingested food penetrate
subcortical areas, such as amygdala and striatum, regulating how much food is consumed.
The hypothalamus then sends signals to cortical areas, such as the OFC, ACC, and insula,
as part of the reward circuitry, where cognitive factors and adiposity signals are integrated.
Finally, a higher order cognitive evaluation determines the individuals eating behavior [83].
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Functional MRI studies have also reported that brain responses to a test meal are not
just a function of calorie intake, but nutrient specific, with differential brain responses to
sugars, lipids, and proteins being reported [84]. Most studies have demonstrated a glucose-
induced decrease in hypothalamic neural response [85–92], with a few exceptions [93,94].
Glucose ingestion shows a stronger reduction in neural response than intravenous admin-
istration, indicating that the incretin effect is important in the hypothalamic response [88].
Glucose-mediated neural responses are CCK-independent, unlike lipid-mediated neural
responses [89]. Unlike glucose, lipid-driven neural responses are abolished by the CCK1
receptor antagonist dexloxiglumide, indicating a CCK-dependent pathway [95]. Lipid-
activated neural responses are also suppressed by ghrelin [96], indicating ghrelin’s role in
attenuating the gut-derived satiety signals. In general, fats attenuate the neural response in
reward areas of the brain [97,98], exerting stronger satiating effects, with a role in regulating
mood possibly explaining comfort eating behaviors [97].
The traditional framework forming the basis of ingestive behavior studies implicate
that pleasure derived from eating overrides homeostatic circuits, whereby the palatable
properties of caloric foods overrule physiological negative feedback that restricts overeat-
ing, resulting in positive energy balance and weight gain [99,100]. This assumption has
recently been challenged by evidence that physiological signals act independently of
pleasure sensations derived from eating and are the major driving force in the ingestive
decision-making process [101]. Subcortical gut–brain pathways sense nutritive properties
independent of palatable properties of food and activate brain reward circuits, as demon-
strated by studies using the flavor-nutrient conditioning paradigm, where flavors are
paired with nutrients or non-nutrient solutions and administered to humans [102,103]. In
the flavor-nutrient conditioning experiments, the striatal and hypothalamic responses are
associated with nutrient sensing and metabolism when flavors are consumed with calories
during conditioning [104]. These studies highlight the significance of gut hormones in
activating the reward systems of the brain and that unconscious motivation for energy
content is not related to the hedonic aspect of food [101]. Palatability may dictate what one
eats rather than reflect how much one eats. IBD patient’s dietary choices may be governed
by sensory properties of food as evidenced by their greater craving for sweet/savory foods
relative to controls [11]. Palatable food choices in CD patients may be influenced by low
mood, impaired inhibition control, and altered gut–brain signaling.
6. Intestinal Inflammation and Modulation of EEC Peptides
6.1. Inflammatory Response and Body Weight
The inflammatory response per se may be a cause of weight loss in IBD. Hypophagic
eating behavior during intestinal inflammation may be partly attributed to the increase in
proinflammatory cytokines such as IL-1 [105], IL-6 [106], and TNF↵ [107]. These regulators
of the inflammatory response may influence metabolism, induce fever, and result in loss
of appetite [108]. Intracerebroventricular infusion of pro-inflammatory cytokines such as
TNF↵ and IL-1  reduce food intake in rats, indicating that inflammation may play a role
in the central regulation of appetite [109]. In gastrointestinal disorders, cytokine-induced
alteration of gastrointestinal motility inhibits feeding. For example, IL-1, TNF↵ decreases,
and IL-10 increases gastrointestinal motility [110,111]. The modulation of intestinal motility
by cytokines, maybe due to direct action in the GI system or an action mediated by the
brain with efferent signaling via the autonomic nervous system [111].
6.2. Examples of Intestinal Inflammation in Mice and Humans
The role of the EEC axis in the induction of altered eating behavior has been described
in a Trichinella spiralis-induced intestinal inflammation murine model [112]. In this study,
mice were infected with T spiralis by oral gavage of 300 larvae, followed by measure-
ment of food intake over 30 days. The peak of severity of intestinal inflammation was
observed 9 days post-infection, which coincided with reduced food intake, weight loss,
and CCK upregulation. This finding may be explained by the juxtaposition of the intestinal
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inflammation and the anatomical location of the CCK-producing I cells. Reduced food
intake was further observed 25 days post-infection in the absence of CCK upregulation,
due to an extraintestinal inflammatory response induced by T spiralis larvae encyst in
the skeleton muscle. Inhibition of CCK receptors by loxiglumide improved food intake
9 days post-infection. However, inhibition of CCK receptors during the extraintestinal
inflammatory phase showed no effect on feeding. Taken together, these findings indicate
that CCK directly contributes to intestinal inflammation-induced hypophagia, but does not
mediate hypophagia induced by extraintestinal inflammation [112].
Early studies of acute intestinal infection demonstrated that patients suffering from
tropical malabsorption had elevated levels of gut hormones [113]. A significant increase
in postprandial CCK was observed in patients with giardiasis [45]. After treatment with
tinidazole, plasma CCK levels were normalized and symptoms such as nausea, bloating,
and anorexia in these patients were ameliorated [45]. It has been suggested that the
endogenous increase in CCK may contribute to symptoms such as nausea and discomfort
observed during intestinal inflammation [45]. Moreover, CCK was also found to reduce
bacterial translocation [114] and increase luminal IgA secretion [115]. Therefore, a reduction
in food intake during a gut infection may be an immunological response that acts as a
protective mechanism against environmental contaminants.
6.3. EEC Peptides and CD
Upregulation of EEC and EEC peptides has been reported in ileal CD. A study [116]
investigating EEC subtypes and EEC markers using terminal ileal tissue from patients with
(i) active ileal CD (n = 38), (ii) inactive ileal CD (n = 5), and colonic tissue from patients with
(iii) active colonic CD (n = 12) (iv) inactive colonic CD (n = 4) and controls (n = 60) reported
a 3.3-fold increase in CgA mRNA expression, 3.1 fold increase in GLP-1 expression, a 1.8
fold increase in neurogenin-3 (Ngn-3) gene expression (a transcription factor involved in
the epithelial cell differentiation to the EEC lineage) in ileal CD compared with controls.
Further, paired like homeobox 2b (Phox2b) (another gene implicated in CD) was found to
be co-localized to EEC and showed a 1.5-fold increase in ileal CD. A significant increase
in terminal ileal chromagranin A (CgA) expressing cells, in active ileal CD tissues was
observed compared with controls. No change in CgA expressing cells was found in the
active colonic CD tissues. A 2.5-fold increase in GLP-1-positive cells was seen in the active
ileal CD tissues compared with control tissues. However, no difference in terminal ileal
PYY expressing cells or mRNA expression was seen between active ileal CD tissue and
controls. These findings collectively indicate an upregulation of EEC in ileal CD.
Investigation of EEC peptides and appetite-related symptoms in response to a mixed
nutrient test meal in active ileal CD patients (n = 12), inactive ileal CD patients (n = 6),
active colonic CD patients (n = 5), and controls (n = 13) showed a 2-fold increase in pre- and
postprandial total PYY plasma levels in active ileal CD patients compared with controls
and active colonic CD patients [117]. Plasma PYY positively correlated with symptoms of
nausea and bloating in the ileal CD patients. No difference in pre- or postprandial active
GLP-1 levels was seen between the groups. It was postulated that GLP-1 was less likely to
play a part in altered appetite in CD. Further, a paradoxical non-significant postprandial
elevation in ghrelin was found in the active ileal CD group. The reassessment of active ileal
CD patients in remission showed that the postprandial PYY and ghrelin levels reverted
to normal control levels, however, this finding is limited by the small number of patients
restudied in remission (n = 6).
A further study [118] investigating postprandial gut hormone levels and gastric emptying
as assessed by 13C-octanoic acid breath test, in response to a standardized breakfast meal in
moderately active CD patients (n = 13) (4 ileal, 4 colonic, and 5 ileal-colonic), in active UC
patients (n = 10), and diverticulitis patients (n = 7) found a 3-fold increase in postprandial
plasma CCK levels compared with controls and was associated with delayed gastric emptying.
Postprandial CCK plasma concentrations were significantly higher in CD patients with
exclusively ileal CD compared with the patients with colonic and ileal-colonic CD, but this
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finding was again limited by the number of exclusively ileal CD patients (n = 4). No difference
in postprandial PYY and GLP-1 was found between CD and controls.
Another study [119] also investigating postprandial gastric emptying as measured
by 13C-octanoic acid breath test and gut hormones response to a test meal in controls (n
= 24), active CD patients (n = 14), and active UC patients (n = 14) found that fasting CCK
levels and maximal postprandial concentrations were similar between IBD patients and
controls, however, patients with UC had significantly lower postprandial CCK levels than
controls and CD patients. No association between CCK plasma levels and gastric emptying
was found contradicting the previous finding by this group [118]. The authors attributed
this inconsistency to the test meal composition containing less lipids and protein, that
primarily stimulate CCK, also this study only had one patient with ileal CD, which may
explain the absence of difference between groups. Fasting GLP-1, PYY, and postprandial
PYY were similar between IBD and controls. However, postprandial GLP-1 responses were
increased in IBD (including CD-control and UC-control) and were associated with delayed
gastric emptying. The reassessment of IBD patients in remission showed accelerated gastric
emptying and normal postprandial increase in GLP-1, indicating that the increased release
of GLP-1 from the inflamed gut mucosa in IBD may result in delayed gastric emptying.
A decrease in fasting small bowel motility as measured by MRI has been observed
in ileal CD patients, attributed to increased fasting GLP-1 and PYY levels relative to con-
trols [120]. Further, CD patients also showed elevated fasting and postprandial adverse GI
symptoms such as fullness, distention, and abdominal pain compared with controls [120].
The adverse symptoms observed in the postprandial phase may be EEC peptide-mediated
alterations in the gut–brain axis, as opposed to altered intestinal physiology.
Taken together, these findings suggest elevated EEC activity in ileal CD. Elevation in
EEC expression at the tissue and plasma level in ileal CD might affect appetite regulation
through changes in CNS signaling pathways. Notably, the increase in tissue and plasma
EEC peptide expression was only observed in patients with ileal CD, whereas patients
with exclusive colonic CD were found to have a normal ileal expression of EEC peptides
and normal postprandial responses to GLP-1 and PYY [116,117], suggesting that disease
location may differentially affect postprandial EEC peptide responses to a meal.
6.4. Modulation of Gut–Brain Signaling in CD
Despite the difference in pathophysiology, similar EEC peptide elevations in PYY,
GLP-1, CCK, and decrease in ghrelin have been found in patients with obesity that have
undergone Roux-en-Y gastric bypass (RYGB) surgery (which involves bypassing most
of the stomach and first section of the small intestine) [121,122]. Postoperatively, these
obese patients exhibit lower activation in brain-hedonic responses to food in relation to
elevated postprandial gut hormones [123–125]. Further, an increase in plasma PYY and
GLP-1 levels were found following an ad libitum test meal in obese patients that underwent
RYGB relative to patients with gastric banding surgery and BMI matched controls [126].
The somatostatin analogue, octreotide-induced suppression of postprandial PYY and
GLP-1 after RYGB correlated positively with an increase in neural signal in the brain
reward system, indicating the role of GLP-1 and PYY in the hedonic response to food [126].
Similarly, after RYGB surgery, inhibition of GLP-1 using receptor antagonist exendin 9–
39, resulted in increased food cue-induced neural response in the caudate nucleus and
increased activation in the insula in response to chocolate milk. The caudate and insula
had shown a decrease in neural response, in the absence of the GLP-1 receptor antagonist,
indicating the role of GLP-1 in reward-driven food intake [124]. Similar findings have been
reported following the parenteral administration of GLP-1 and PYY in healthy subjects [127].
Fatty-acids, specifically those with an acyl chain C12 or more (e.g., dodecanoate) lead to a
CCK-dependent increase in neural responses in the brainstem, the pons, hypothalamus,
cerebellum, and the motor cortical areas [96]. Mechanistic inhibition through the CCK type 1
receptor inhibitor dexloxiglumide causes a reversal in neural responses and a normalization
of appetite-related scores [96]. Although an exaggerated EEC peptide response to food
Nutrients 2021, 13, 981 9 of 17
intake has been described in ileal CD, the gut–brain axis has not yet been investigated.
Future studies are warranted to investigate whether ileal CD patients have altered gut and
brain responses to specific nutrients, due to upregulation in EEC peptides, resulting in
changes in appetite and eating behavior.
7. The Effect of Intestinal and Systemic Inflammation on the CNS
Intestinal inflammation and abdominal pain may activate central sensitization pathways
that convey visceral nociceptive afferent signals from the gut to the brain [128,129]. Addition-
ally, psychosocial distress may also affect symptom perception and gut function [129]. These
observations may imply a role for the CNS in chronic symptom generation and perception
in IBD. Multiple factors such as systemic inflammatory response [130,131], fatigue [132,133],
abdominal pain [134], psychological comorbidities [135], and medication use [136–138], may
be linked with brain structural and functional abnormalities in IBD. Alterations in brain
structure have been reported in CD patients with extraintestinal inflammation (EIM) relative
to CD patients without EIM in the insula (pain processing) and the right ACC (emotion and
impulse control), which may be attributed to systemic inflammation [131]. Multiple structural
MRI, resting state, and task fMRI studies have been conducted in IBD. A meta-analysis inves-
tigating structural and functional brain changes in CD in remission found that CD patients
had reduced resting-state functional connectivity in the paracentral lobule (motor function)
and cingulate gyrus and reduced grey matter volume in the medial frontal gyrus (executive
function) [139]. However, currently, there is a lack of food and eating behavior-specific studies,
to understand the structural and functional brain changes associated with food intake and
eating behavior in intestinal inflammation.
The conceptual framework in Figure 1 depicts how intestinal inflammation-induced
alterations in the gut–brain axis and disease symptoms may influence eating behaviors.




Figure 1. Conceptual framework. 
Table 1 provides a summary of the key studies investigating the upregulation of EEC 
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8. Conclusions
In summary, a complex interplay of gut peptides, altered gut–brain signaling, cog-
nitive, psychological factors, disease-related symptoms, and inflammatory burden may
ultimately guide eating behavior in intestinal inflammation. The studies mentioned in this
review have several limitations. The studies investigating upregulation of EEC peptides in
ileal CD are limited by sample size, patient standardization with variations in distribution
and severity of inflammation, concomitant medication use, genotypes and triggers, and
the nutrient composition of test meals used to assess postprandial physiological effects.
Presently, there is a lack of food and eating behavior-specific fMRI task studies in IBD.
Hence, future research could investigate food-induced alterations in gut–brain signaling in
IBD patients using fMRI, to better understand the role of the brain in appetite control in
intestinal inflammation. Further, the use of food-based impulsivity tasks will aid the under-
standing of impulse-driven eating behaviors in IBD patients. More studies need to assess
patients in both the active phase of the disease and in remission, to see if the behavioral and
CNS changes are reversible and associated with improved disease outcomes. Future IBD
studies could use a non-gastrointestinal chronic disease group (such as rheumatoid arthritis
or psoriasis) as comparator groups to dissect the relationship between gastrointestinal,
systemic inflammation, and structural/functional brain alterations. Longitudinal studies
are warranted to understand the effect of diet and disordered eating behaviors on disease
course. A better understanding of the role of EEC peptides in altered eating behavior,
malnutrition, and in the modulation of the gut–brain axis is relevant in elucidating new
therapeutic pathways in CD treatment, thus improving nutritional status, disease out-
comes, and quality of life. Dietetic advice for healthy eating is recommended to improve
disordered eating traits. Psychological, cognitive, and behavioral therapeutic interventions
may be beneficial to manage disease-related symptoms such as low mood, chronic fatigue,
abdominal pain, increased self-monitoring, and impulsivity that may negatively influence
eating behaviors.
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